BioSpace News Archive

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic” or the “Company”), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers, announces that the engineering and construction of IzoView

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 25, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announced that GSK will transfer its NY-ESO cell therapy program and the right to the PRAME cell therapy program to Adaptimmune.

Marvel Biosciences Inc. (TSXV: MRVL) (the “Company” or “Marvel”) is pleased to announce it has completed its maximum tolerated dose (MTD) toxicology study in dogs for its product MB-204, further validating the Company’s lead drug candidate low toxicity characteristic.

Almaden Genomics has launched g.nome™, a cloud-native platform designed to streamline genomic workflows and accelerate genomic discovery.

ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV.

Hospital for Special Surgery announced a $21M Series A to launch RightMove Powered by HSS™, an independent for-profit company, whose mission is to make high quality, patient-focused virtual musculoskeletal physical therapy available to all Americans.

Researchers at the UCSF QBI Coronavirus Research Group have uncovered how the SARS-CoV-2 variants of concern differ in their ability to manipulate human cells on a molecular level during infection.

Neuronetics, Inc. announced healthcare policy updates that increase patient access to NeuroStar Advanced Therapy for Mental Health transcranial magnetic stimulation (TMS).

Enspectra Health, a digital health company pioneering the field of virtual biopsies, announced that the first subject has been enrolled in its VISTA US Pivotal Study. VIO™ Imaging for Skin Tissue Assessment (VISTA) is a prospective, multicenter study designed to demonstrate the safety and effectiveness of the VIO System.

Cellevolve Bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CE-VST01-JC, a JC Virus Specific T Cell Therapy (JC-VST) that is being studied for the treatment of progressive multifocal leukoencephalopathy (PML). CE-VST01-JC also received FDA orphan drug designation.